TABLE OF CONTENTS
1. EXECUTIVE SUMMARY
2. MARKET INTRODUCTION
2.1. Definition
2.2. Scope of the Study
2.2.1. Research Objective
2.2.2. Assumptions
2.2.3.Limitations
3. RESEARCH METHODOLOGY
3.1. Overview
3.2. Data Mining
3.3. Secondary Research
3.4. Primary Research
3.4.1. Primary Interviews and Information Gathering Process
3.4.2.Breakdown of Primary Respondents
3.5. Forecasting Model
3.6. Market Size Estimation
3.6.1. Bottom-Up Approach
3.6.2. Top-Down Approach
3.7. Data Triangulation
3.8. Validation
4. MARKET DYNAMICS
4.1. Overview
4.2. Drivers
4.3. Restraints
4.4. Opportunities
5. MARKET FACTOR ANALYSIS
5.1. Value Chain Analysis
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining Power of Suppliers
5.2.2. Bargaining Power of Buyers
5.2.3. Threat of New Entrants
5.2.4. Threat of Substitutes
5.2.5. Intensity of Rivalry
5.3. COVID-19 Impact Analysis
5.3.1. Market Impact Analysis
5.3.2. Regional Impact
5.3.3. Opportunity and Threat Analysis
6. UNITED STATES GENOME EDITING ENGINEERING, BY TECHNOLOGY
6.1. Overview
6.2. Meganucleases
6.3. Cas9
6.4. TALENs/MegaTALs
6.5. ZFN
6.6. Others
7. UNITED STATES GENOME EDITING ENGINEERING, BY DELIVERY METHOD
7.1. Overview
7.2. Ex-vivo
7.3. In-vivo
8. UNITED STATES GENOME EDITING ENGINEERING, BY MODE
8.1. Overview
8.2. Contract
8.3. In-house
9. UNITED STATES GENOME EDITING ENGINEERING, BY END-USE
9.1. Overview
9.2. Biotechnology & Pharmaceutical Companies
9.3. Academic & Government Research Institutes
9.4. Contract Research Organizations
10. UNITED STATES GENOME EDITING ENGINEERING, BY APPLICATION
10.1. Overview
10.2. Genetic Engineering
10.3. Clinical Applications
11. COMPETITIVE LANDSCAPE
11.1. Overview
11.2. Competitive Analysis
11.3. Market Share Analysis
11.4. Major Growth Strategy in the United States Genome Editing Engineering,
11.5. Competitive Benchmarking
11.6. Leading Players in Terms of Number of Developments in the United States Genome Editing Engineering,
11.7. Key Developments and Growth Strategies
11.7.1. New Product Launch/Service Deployment
11.7.2. Merger &Acquisitions
11.7.3. Joint Ventures
11.8. Major Players Financial Matrix
11.8.1. Sales & Operating Income, 2022
11.8.2. Major Players R&D Expenditure.2022
12. COMPANY PROFILES
12.1. Merck KGaA
12.1.1. Company Overview
12.1.2. Financial Overview
12.1.3. Products Offered
12.1.4. Key Developments
12.1.5. SWOT Analysis
12.1.6. Key Strategies
12.2. Cibus
12.2.1. Company Overview
12.2.2. Financial Overview
12.2.3. Products Offered
12.2.4. Key Developments
12.2.5. SWOT Analysis
12.2.6. Key Strategies
12.3. Sangamo
12.3.1. Company Overview
12.3.2. Financial Overview
12.3.3. Products Offered
12.3.4. Key Developments
12.3.5. SWOT Analysis
12.3.6. Key Strategies
12.4. Editas Medicine
12.4.1. Company Overview
12.4.2. Financial Overview
12.4.3. Products Offered
12.4.4. Key Developments
12.4.5. SWOT Analysis
12.4.6. Key Strategies
12.5. Precision Biosciences,
12.5.1. Company Overview
12.5.2. Financial Overview
12.5.3. Products Offered
12.5.4. Key Developments
12.5.5. SWOT Analysis
12.5.6. Key Strategies
12.6. CRISPR Therapeutics
12.6.1. Company Overview
12.6.2. Financial Overview
12.6.3. Products Offered
12.6.4. Key Developments
12.6.5. SWOT Analysis
12.6.6. Key Strategies
12.7. Intellia Therapeutics, Inc.,
12.7.1. Company Overview
12.7.2. Financial Overview
12.7.3. Products Offered
12.7.4. Key Developments
12.7.5. SWOT Analysis
12.7.6. Key Strategies
12.8. Caribou Biosciences, Inc.
12.8.1. Company Overview
12.8.2. Financial Overview
12.8.3. Products Offered
12.8.4. Key Developments
12.8.5. SWOT Analysis
12.8.6. Key Strategies
12.9. Cellectis S.A.
12.9.1. Company Overview
12.9.2. Financial Overview
12.9.3. Products Offered
12.9.4. Key Developments
12.9.5. SWOT Analysis
12.9.6. Key Strategies
12.10. AstraZeneca
12.10.1. Company Overview
12.10.2. Financial Overview
12.10.3. Products Offered
12.10.4. Key Developments
12.10.5. SWOT Analysis
12.10.6. Key Strategies
12.11. Takara Bio USA
12.11.1. Company Overview
12.11.2. Financial Overview
12.11.3. Products Offered
12.11.4. Key Developments
12.11.5. SWOT Analysis
12.11.6. Key Strategies
12.12. Horizon Discovery Group plc
12.12.1. Company Overview
12.12.2. Financial Overview
12.12.3. Products Offered
12.12.4. Key Developments
12.12.5. SWOT Analysis
12.12.6. Key Strategies
12.13. Integrated DNA Technologies, Inc.
12.13.1. Company Overview
12.13.2. Financial Overview
12.13.3. Products Offered
12.13.4. Key Developments
12.13.5. SWOT Analysis
12.13.6. Key Strategies
12.14. Egenesis Inc.
12.14.1. Company Overview
12.14.2. Financial Overview
12.14.3. Products Offered
12.14.4. Key Developments
12.14.5. SWOT Analysis
12.14.6. Key Strategies
12.15. GenScript
12.15.1. Company Overview
12.15.2. Financial Overview
12.15.3. Products Offered
12.15.4. Key Developments
12.15.5. SWOT Analysis
12.15.6. Key Strategies
12.16. New England Biolabs
12.16.1. Company Overview
12.16.2. Financial Overview
12.16.3. Products Offered
12.16.4. Key Developments
12.16.5. SWOT Analysis
12.16.6. Key Strategies
12.17. OriGene Technologies, Inc.
12.17.1. Company Overview
12.17.2. Financial Overview
12.17.3. Products Offered
12.17.4. Key Developments
12.17.5. SWOT Analysis
12.17.6. Key Strategies
12.18. Lonza
12.18.1. Company Overview
12.18.2. Financial Overview
12.18.3. Products Offered
12.18.4. Key Developments
12.18.5. SWOT Analysis
12.18.6. Key Strategies
12.19. Thermo Fisher Scientific, Inc.
12.19.1. Company Overview
12.19.2. Financial Overview
12.19.3. Products Offered
12.19.4. Key Developments
12.19.5. SWOT Analysis
12.19.6. Key Strategies
13. APPENDIX
13.1. References
13.2. Related Reports
LIST OF TABLES
TABLE 1 UNITED STATES GENOME EDITING ENGINEERING, SYNOPSIS, 2018-2032
TABLE 2 UNITED STATES GENOME EDITING ENGINEERING, ESTIMATES & FORECAST, 2018-2032(USD BILLION)
TABLE 3 UNITED STATES GENOME EDITING ENGINEERING, BY TECHNOLOGY, 2018-2032 (USD BILLION)
TABLE 4 UNITED STATES GENOME EDITING ENGINEERING, BY DELIVERY METHOD, 2018-2032 (USD BILLION)
TABLE 5 UNITED STATES GENOME EDITING ENGINEERING, BY MODE, 2018-2032 (USD BILLION)
TABLE 6 UNITED STATES GENOME EDITING ENGINEERING, BY END-USE, 2018-2032 (USD BILLION)
TABLE 7 UNITED STATES GENOME EDITING ENGINEERING, BY APPLICATION, 2018-2032 (USD BILLION)
LIST OF FIGURES
FIGURE 1 RESEARCH PROCESS
FIGURE 2 MARKET STRUCTURE FOR THE UNITED STATES GENOME EDITING ENGINEERING
FIGURE 3 MARKET DYNAMICS FOR THE UNITED STATES GENOME EDITING ENGINEERING
FIGURE 4 UNITED STATES GENOME EDITING ENGINEERING, SHARE (%), BY TECHNOLOGY, 2022
FIGURE 5 UNITED STATES GENOME EDITING ENGINEERING, SHARE (%), BY DELIVERY METHOD, 2022
FIGURE 6 UNITED STATES GENOME EDITING ENGINEERING, SHARE (%), BY MODE, 2022
FIGURE 7 UNITED STATES GENOME EDITING ENGINEERING, SHARE (%), BY END-USE, 2022
FIGURE 8 UNITED STATES GENOME EDITING ENGINEERING, SHARE (%), BY APPLICATION, 2022
FIGURE 9 UNITED STATES GENOME EDITING ENGINEERING: COMPANY SHARE ANALYSIS, 2022 (%)
FIGURE 10 MERCK KGAA: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 11 MERCK KGAA: SWOT ANALYSIS
FIGURE 12 CIBUS: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 13 CIBUS: SWOT ANALYSIS
FIGURE 14 SANGAMO : FINANCIAL OVERVIEW SNAPSHOT
FIGURE 15 SANGAMO: SWOT ANALYSIS
FIGURE 16 EDITAS MEDICINE: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 17 EDITAS MEDICINE: SWOT ANALYSIS
FIGURE 18 PRECISION BIOSCIENCES: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 19 PRECISION BIOSCIENCES: SWOT ANALYSIS
FIGURE 20 CRISPR THERAPEUTICS: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 21 CRISPR THERAPEUTICS: SWOT ANALYSIS
FIGURE 22 INTELLIA THERAPEUTICS, INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 23 INTELLIA THERAPEUTICS, INC.: SWOT ANALYSIS
FIGURE 24 CARIBOU BIOSCIENCES, INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 25 CARIBOU BIOSCIENCES, INC.: SWOT ANALYSIS
FIGURE 26 CELLECTIS S.A.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 27 CELLECTIS S.A.: SWOT ANALYSIS
FIGURE 28 ASTRAZENECA: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 29 ASTRAZENECA: SWOT ANALYSIS
FIGURE 30 TAKARA BIO USA, : FINANCIAL OVERVIEW SNAPSHOT
FIGURE 31 TAKARA BIO USA, : SWOT ANALYSIS
FIGURE 32 HORIZON DISCOVERY GROUP PLC: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 33 HORIZON DISCOVERY GROUP PLC: SWOT ANALYSIS
FIGURE 34 INTEGRATED DNA TECHNOLOGIES, INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 35 INTEGRATED DNA TECHNOLOGIES, INC.: SWOT ANALYSIS
FIGURE 36 EGENESIS INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 37 EGENESIS INC.: SWOT ANALYSIS
FIGURE 38 GENSCRIPT: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 39 GENSCRIPT: SWOT ANALYSIS
FIGURE 40 NEW ENGLAND BIOLABS: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 41 NEW ENGLAND BIOLABS: SWOT ANALYSIS
FIGURE 42 ORIGENE TECHNOLOGIES, INC..: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 43 ORIGENE TECHNOLOGIES, INC.: SWOT ANALYSIS
FIGURE 44 LONZA: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 45 LONZA SWOT ANALYSIS
FIGURE 46 THERMO FISHER SCIENTIFIC, INC: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 47 THERMO FISHER SCIENTIFIC, INC: SWOT ANALYSIS
